CPA
ARKG icon

Capital Performance Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Capital Performance Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27
Closed -$691 – 346
2024
Q3 		$691 Buy
+27
New +$688 ﹤0.01% 2093

Other funds holding ARKG

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Capital Performance Advisors's ARKG Position: Q4 2024 in Review

Capital Performance Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2024, closing a stake of 27 shares — an estimated $691 sold.

Capital Performance Advisors first reported a position in ARKG in Q3 2024 and held it in 1 quarter. The position peaked at $691 in Q3 2024. 241 funds tracked by Wall St. Rank hold ARKG as of Q4 2024.

  • Capital Performance Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 27 ARK Genomic Revolution ETF shares in Q4 2024, an estimated $691.
  • Capital Performance Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's ARK Genomic Revolution ETF position peaked at $691 in Q3 2024.
  • 241 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.